000155752 001__ 155752
000155752 005__ 20240323120023.0
000155752 0247_ $$2doi$$a10.1007/s00228-020-03068-8
000155752 0247_ $$2pmid$$apmid:33442768
000155752 0247_ $$2pmc$$apmc:PMC8184524
000155752 0247_ $$2ISSN$$a0031-6970
000155752 0247_ $$2ISSN$$a0369-9498
000155752 0247_ $$2ISSN$$a1432-1041
000155752 0247_ $$2altmetric$$aaltmetric:97758050
000155752 037__ $$aDZNE-2021-00920
000155752 041__ $$aEnglish
000155752 082__ $$a610
000155752 1001_ $$00000-0003-4414-114X$$aAhn, Nayeon$$b0
000155752 245__ $$aLack of association between proton pump inhibitor use and brain aging: a cross-sectional study.
000155752 260__ $$aNew York$$bSpringer$$c2021
000155752 3367_ $$2DRIVER$$aarticle
000155752 3367_ $$2DataCite$$aOutput Types/Journal article
000155752 3367_ $$0PUB:(DE-HGF)16$$2PUB:(DE-HGF)$$aJournal Article$$bjournal$$mjournal$$s1711112872_19997
000155752 3367_ $$2BibTeX$$aARTICLE
000155752 3367_ $$2ORCID$$aJOURNAL_ARTICLE
000155752 3367_ $$00$$2EndNote$$aJournal Article
000155752 520__ $$aDue to conflicting scientific evidence for an increased risk of dementia by intake of proton pump inhibitors (PPIs), this study investigates associations between PPI use and brain volumes, estimated brain age, and cognitive function in the general population.Two surveys of the population-based Study of Health in Pomerania (SHIP) conducted in Northeast Germany were used. In total, 2653 participants underwent brain magnetic resonance imaging (MRI) and were included in the primary analysis. They were divided into two groups according to their PPI intake and compared with regard to their brain volumes (gray matter, white matter, total brain, and hippocampus) and estimated brain age. Multiple regression was used to adjust for confounding factors. Cognitive function was evaluated by the Verbal Learning and Memory Test (VLMT) and the Nuremberg Age Inventory (NAI) and put in relation to PPI use.No association was found between PPI use and brain volumes or the estimated brain age. The VLMT score was 1.11 lower (95% confidence interval: - 2.06 to - 0.16) in immediate recall, and 0.72 lower (95% CI: - 1.22 to - 0.22) in delayed recall in PPI users than in non-users. PPI use was unrelated to the NAI score.The present study does not support a relationship between PPI use and brain aging.
000155752 536__ $$0G:(DE-HGF)POF4-353$$a353 - Clinical and Health Care Research (POF4-353)$$cPOF4-353$$fPOF IV$$x0
000155752 588__ $$aDataset connected to CrossRef, PubMed, , Journals: pub.dzne.de
000155752 650_7 $$2Other$$aBrain volume
000155752 650_7 $$2Other$$aCognitive impairment
000155752 650_7 $$2Other$$aDementia
000155752 650_7 $$2Other$$aMagnetic resonance imaging
000155752 650_7 $$2Other$$aProton pump inhibitors
000155752 650_2 $$2MeSH$$aAdult
000155752 650_2 $$2MeSH$$aAged
000155752 650_2 $$2MeSH$$aAged, 80 and over
000155752 650_2 $$2MeSH$$aAging: drug effects
000155752 650_2 $$2MeSH$$aBrain: drug effects
000155752 650_2 $$2MeSH$$aCognition: drug effects
000155752 650_2 $$2MeSH$$aCross-Sectional Studies
000155752 650_2 $$2MeSH$$aFemale
000155752 650_2 $$2MeSH$$aGermany
000155752 650_2 $$2MeSH$$aHumans
000155752 650_2 $$2MeSH$$aMale
000155752 650_2 $$2MeSH$$aMiddle Aged
000155752 650_2 $$2MeSH$$aProton Pump Inhibitors: administration & dosage
000155752 650_2 $$2MeSH$$aProton Pump Inhibitors: adverse effects
000155752 650_2 $$2MeSH$$aYoung Adult
000155752 7001_ $$aFrenzel, Stefan$$b1
000155752 7001_ $$0P:(DE-2719)2810491$$aWittfeld, Katharina$$b2$$udzne
000155752 7001_ $$aBülow, Robin$$b3
000155752 7001_ $$aVölzke, Henry$$b4
000155752 7001_ $$aLerch, Markus M$$b5
000155752 7001_ $$aChenot, Jean-Francois$$b6
000155752 7001_ $$aSchminke, Ulf$$b7
000155752 7001_ $$aNolde, Michael$$b8
000155752 7001_ $$aAmann, Ute$$b9
000155752 7001_ $$aMeisinger, Christa$$b10
000155752 7001_ $$aLinseisen, Jakob$$b11
000155752 7001_ $$aBaumeister, Sebastian E$$b12
000155752 7001_ $$0P:(DE-2719)2811781$$aGrabe, Hans Jörgen$$b13$$udzne
000155752 7001_ $$aRückert-Eheberg, Ina-Maria$$b14
000155752 773__ $$0PERI:(DE-600)1459058-X$$a10.1007/s00228-020-03068-8$$gVol. 77, no. 7, p. 1039 - 1048$$n7$$p1039 - 1048$$tEuropean journal of clinical pharmacology$$v77$$x1432-1041$$y2021
000155752 8564_ $$uhttps://pub.dzne.de/record/155752/files/DZNE-2021-00920.pdf$$yOpenAccess
000155752 8564_ $$uhttps://pub.dzne.de/record/155752/files/DZNE-2021-00920.pdf?subformat=pdfa$$xpdfa$$yOpenAccess
000155752 909CO $$ooai:pub.dzne.de:155752$$popenaire$$popen_access$$pVDB$$pdriver$$pdnbdelivery
000155752 9101_ $$0I:(DE-588)1065079516$$6P:(DE-2719)2810491$$aDeutsches Zentrum für Neurodegenerative Erkrankungen$$b2$$kDZNE
000155752 9101_ $$0I:(DE-588)1065079516$$6P:(DE-2719)2811781$$aDeutsches Zentrum für Neurodegenerative Erkrankungen$$b13$$kDZNE
000155752 9131_ $$0G:(DE-HGF)POF4-353$$1G:(DE-HGF)POF4-350$$2G:(DE-HGF)POF4-300$$3G:(DE-HGF)POF4$$4G:(DE-HGF)POF$$aDE-HGF$$bGesundheit$$lNeurodegenerative Diseases$$vClinical and Health Care Research$$x0
000155752 9141_ $$y2021
000155752 915__ $$0LIC:(DE-HGF)CCBY4$$2HGFVOC$$aCreative Commons Attribution CC BY 4.0
000155752 915__ $$0StatID:(DE-HGF)0200$$2StatID$$aDBCoverage$$bSCOPUS$$d2023-03-30
000155752 915__ $$0StatID:(DE-HGF)0160$$2StatID$$aDBCoverage$$bEssential Science Indicators$$d2021-01-30
000155752 915__ $$0StatID:(DE-HGF)1050$$2StatID$$aDBCoverage$$bBIOSIS Previews$$d2023-03-30
000155752 915__ $$0StatID:(DE-HGF)1190$$2StatID$$aDBCoverage$$bBiological Abstracts$$d2021-01-30
000155752 915__ $$0StatID:(DE-HGF)0600$$2StatID$$aDBCoverage$$bEbsco Academic Search$$d2023-03-30
000155752 915__ $$0StatID:(DE-HGF)0100$$2StatID$$aJCR$$bEUR J CLIN PHARMACOL : 2021$$d2023-03-30
000155752 915__ $$0StatID:(DE-HGF)1030$$2StatID$$aDBCoverage$$bCurrent Contents - Life Sciences$$d2023-03-30
000155752 915__ $$0StatID:(DE-HGF)0113$$2StatID$$aWoS$$bScience Citation Index Expanded$$d2021-01-30
000155752 915__ $$0StatID:(DE-HGF)3002$$2StatID$$aDEAL Springer$$d2021-01-30$$wger
000155752 915__ $$0StatID:(DE-HGF)0150$$2StatID$$aDBCoverage$$bWeb of Science Core Collection$$d2023-03-30
000155752 915__ $$0StatID:(DE-HGF)9900$$2StatID$$aIF < 5$$d2023-03-30
000155752 915__ $$0StatID:(DE-HGF)0510$$2StatID$$aOpenAccess
000155752 915__ $$0StatID:(DE-HGF)0030$$2StatID$$aPeer Review$$bASC$$d2023-03-30
000155752 915__ $$0StatID:(DE-HGF)0300$$2StatID$$aDBCoverage$$bMedline$$d2023-03-30
000155752 915__ $$0StatID:(DE-HGF)1110$$2StatID$$aDBCoverage$$bCurrent Contents - Clinical Medicine$$d2023-03-30
000155752 915__ $$0StatID:(DE-HGF)0199$$2StatID$$aDBCoverage$$bClarivate Analytics Master Journal List$$d2023-03-30
000155752 9201_ $$0I:(DE-2719)5000001$$kAG Grabe$$lBiomarkers of Dementia in the General Population$$x0
000155752 9201_ $$0I:(DE-2719)1510600$$kAG Hoffmann$$lTranslational Health Care Research$$x1
000155752 980__ $$ajournal
000155752 980__ $$aVDB
000155752 980__ $$aUNRESTRICTED
000155752 980__ $$aI:(DE-2719)5000001
000155752 980__ $$aI:(DE-2719)1510600
000155752 9801_ $$aFullTexts